Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients
Research
[키워드] 95% confidence interval
adjusted
age
anticoagulation
association
bleeding
body mass index
Characteristics
confidence interval
COVID-19
COVID-19 patient
Cox proportional hazard
Critical
Critical care
Critically ill
cumulative
daily dose
death
develop
dosage
dose
doses
Dosing
eligible
evaluate
groups
hazard ratio
High dose
High-dose
ICU admission
incidence
initial
intensive care unit
invasive respiratory support
Local
low dose
low molecular weight heparin
low-dose
lower mortality
lower risk
medium
medium dose
Mortality
not differ
Patient
Physiology
Prophylaxis
proportion
recommendations
Registered
Respiratory failure
Result
Retrospective study
risk
risk of death
SARS-CoV-2
score
Sex
three group
thromboembolic complications
Thromboembolic event
Thromboembolism
Thromboprophylaxis
thrombosis
was used
[DOI] 10.1186/s13054-020-03375-7 PMC 바로가기 [Article Type] Research
[DOI] 10.1186/s13054-020-03375-7 PMC 바로가기 [Article Type] Research